在患有慢性心力衰竭的患者中,普雷加巴林启动对利尿剂需求的影响
Journal of the American Pharmacists Association : JAPhA
|March 3, 2024
概括
这项研究发现,在心力衰竭患者中启动普雷加巴林并没有显著改变他们的循环利尿剂需求. 在这个人群中使用普雷加巴林需要谨慎,尽管在利尿剂剂量上没有观察到任何变化.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于普雷加巴林对心力衰竭患者的影响的数据有限,主要来自病例报告和队列研究.
- 了解药物相互作用和对现有治疗方法的影响对于管理心力衰竭至关重要.
研究的目的:
- 为了研究在被诊断为心力衰竭的患者中启动普雷加巴林对利尿剂需求的影响.
- 评估在开始服用普雷加巴林治疗后循环利尿剂剂量的变化.
主要方法:
- 在2014年至2021年期间开始服用普雷加巴林的58名心力衰竭患者的回顾性分析.
- 主要结局:在开始服用普雷加巴林6个月后,循环利尿剂剂量 (富洛塞米德等效剂) 的中位变化.
主要成果:
- 在尿剂剂量变化的初级结果中没有观察到统计学上显著的差异 (P = 0.162).
- 二次结果也显示没有统计学意义.
- 在pregabalin剂量和观察到的结果之间没有发现相关性.
结论:
- 这项研究是迄今为止关于在开始服用普雷加巴林后心力衰竭患者的利尿剂剂量调整的最大分析.
- 虽然没有检测到中位利尿剂剂量的显著变化,但仍建议在心力衰竭患者中谨慎使用普雷加巴林.
相关概念视频
Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
Antihypertensive Drugs: Action of Diuretics
690
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
690
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antihypertensive Drugs: Potassium-Sparing Diuretics
545
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
545


